Jul 20, 2023 | Press Releases
CULVER CITY, Calif., July 20, 2023 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a...
Jul 10, 2023 | Press Releases
CULVER CITY, Calif., July 10, 2023 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced findings from a Phase 1 study showing that allogeneic cytokine-induced memory-like (CIML) natural killer (NK) cells used in combination...
May 22, 2023 | Press Releases
CULVER CITY, Calif., May 22, 2023 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong, M.D., will participate in a fireside...
Apr 25, 2023 | Press Releases
The Phase 2b cancer vaccine trial will study a multiple vaccination approach called ‘Tri-Ad5’ that uses three ImmunityBio vaccines in combination with the company’s IL-15 superagonist N-803, to potentially reduce the risk of developing colorectal and other cancers in...
Apr 24, 2023 | Press Releases
CULVER CITY, Calif., April 24, 2023 — ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that Executive Chairman and Global Chief Scientific and Medical Officer Patrick Soon-Shiong, M.D., has been invited to deliver the 2023...
Feb 16, 2023 | Press Releases
A positive difference in physical function in responders versus non-responders was noted The study indicates a favorable risk/benefit ratio and quality of life following N-803 plus BCG is comparable to BCG alone CULVER CITY, Calif., February 16, 2023 — ImmunityBio,...
